Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2017; 7(9): 191-198


Antifibrotic candidates of Selenium nanoparticles and selenium in the experimental model

Aziza B. Shalby, Mohamed Diaa Abd El-Maksoud, Ahmed E. Abdel Moneim, Hanaa H. Ahmed.




Abstract

This research was designed to compare the efficacy of selenium in nanoscale (SeNPs) with its free form (Se) against liver fibrosis induced by thioacetamide (TAA) in rats. In a completely randomized design, 60 adult female rats were distributed as: Group (1) control (received saline) and other three groups received TAA to induce liver fibrosis (100 mg/kg b.wt of three times a week for 6 weeks). Fifteen rats were termed TAA (Group 2). Rats in group (3) were simultaneously administered SeNPs (0.48 mg/kg/b.wt) orally (TAA+SeNPs). Rats in group (4) were simultaneously administered Se (0.48 mg/kg/b.wt) orally (TAA+Se). TAA injection enhanced liver enzymes activity, oxidative stress markers and inflammatory mediators, while suppressed the activity of the antioxidant enzymes activity versus the control group. SeNPs as well as Se supplementation blunted liver enzymes activity, oxidative stress indicators and inflammatory intermediates, while potentiated the activity of the antioxidant enzymes relative to TAA group. Histological investigation of liver tissue appreciated the biochemical findings. A forementioned data clearly indicate that the mitigation of oxidative stress and inflammation may be the probable mechanisms by which SeNPs or Se can offer their antifibrotic action. Worthmentioning, SeNPs showed superior effect above Se in its free form in this respect.

Key words: Selenium nanoparticles; Liver fibrosis; Inflammation; Antifibrotic action;Rats.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.